Latest / Breastcancer.org Podcast

Talzenna Patient-Reported Outcomes
Dr. Jennifer Litton, a board-certified medical oncologist and professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where she is chief of the Section of Clinical Research and Drug Development for Breast Cancer. She also is a member of the Breast Immuno-Oncology Task Force of the National Cancer Institute.
At the American Association for Cancer Research virtual annual meeting, Dr. Litton presented results from the EMBRACA trial, looking at using Talzenna (chemical name: talazoparib), a type of medicine called a PARP inhibited, to treat…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.